Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Savadelis, Michael Spicer, Paul Kelly, Thomas McNaughton, John Lewis, Hirday Bhathal

Premium

Orchid Biosciences CFO Andrew Savadelis has been replaced by Michael Spicer. Spicer has been vice president of finance at Orchid since December 2001, when the company acquired Lifecodes , where he was vice president, CFO, treasurer, and secretary, according to the company. This management change comes a little more than one month after Paul Kelly took the helm of Orchid and laid off employees and restructured the company’s personalized medicine business unit (see SNPtech Reporter, June 6, 2003).


Zyomyx has tapped Thomas McNaughton to be vice president of intellectual property. McNaughton will initially be responsible for “expanding and enforcing” Zyomyx’ patent portfolio, and will provide general legal strategy and support for the manufacture, sale, and distribution of the firm’s Protein Profiling Biochip System and biochips. McNaughton, who will report to CEO Robert Monaghan, comes to Zyomyx from Aclara Biosciences, where he was vice president of legal affairs.

Zyomyx has also hired John Lewis as vice president of sales and marketing. He will take over the post vacated by Hirday Bhathal, who stepped down as the company’s vice president of corporate development.

Lewis will be responsible for “all customer facing operations” including sales, marketing, and technical support.

Lewis, who will also report to Monaghan, comes to Zyomyx from BD Biosciences Clontech, where he was vice president of customer development and world-wide technical support.

 

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more